AAV

#AAV #Gene therapy #Thermo Fisher Scientific #Webinar

Analysis of full and empty particles in AAV vectors for gene therapy

This advertorial appeared in DDW Volume 25 – Issue 4, Fall 2024 Read the digital issue In a recent DDW event, supported by Thermo Fisher Scientific, Professor Susumu Uchiyama, Department of Biotechnology, Graduate School of Engineering, Osaka University, presented his work around adeno-associated virus (AAV) characterisation using cryo-electron microscopy. Cryo-EM application… Read More

#Exclusive Content

#AAV #Cryo-EM #cryo-microscopy #Drug discovery #Gene therapy #Webinar

This week: Discover innovative approaches in AAV vector analysis

In a webinar on 5 September, Professor Susumu Uchiyama, Department of Biotechnology, Graduate School of Engineering, Osaka University, will present his work around adeno-associated virus (AAV) characterisation using cryo-electron microscopy. The event is hosted by DDW and supported by Thermo Fisher Scientific. In… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#News

#AAV #Cryo-EM #cryo-microscopy #Drug discovery #Gene therapy #Webinar

Register now: AAV characterisation using cryo-EM and deep learning

In a webinar on 5 September, Professor Susumu Uchiyama, Department of Biotechnology, Graduate School of Engineering, Osaka University, will present his work around adeno-associated virus (AAV) characterisation using cryo-electron microscopy. The event is hosted by DDW and supported by Thermo Fisher Scientific. In… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#News

Cell and gene therapy concept
#AAV #Cell and gene therapy #Gene delivery #Gene therapy #Viral vectors

Improving viral vector safety for gene therapies

Dr Andrea O'Hara, Senior Product Manager at Azenta Life Sciences asks why integration site analysis (ISA) is critical for the safety and efficacy of viral vectors for gene therapy. Cell and gene therapies have revolutionised how clinicians treat a variety of diseases including cancer, blindness, and metabolic disorders. With these… Read More

#Exclusive Content

#AAV #Cryo-EM #cryo-microscopy #Drug discovery #Gene therapy #Webinar

Webinar: Discover AAV characterisation using cryo-EM

In a webinar on 5 September, Professor Susumu Uchiyama, Department of Biotechnology, Graduate School of Engineering, Osaka University, will present his work around adeno-associated virus (AAV) characterisation using cryo-electron microscopy. The event is hosted by DDW and supported by Thermo Fisher Scientific. In… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#News

#AAV #Cryo-EM #cryo-microscopy #Drug discovery #Gene therapy #Webinar

Webinar: Adeno-associated virus vectors for gene therapy

In a webinar on 5 September, Professor Susumu Uchiyama, Department of Biotechnology, Graduate School of Engineering, Osaka University, will present his work around adeno-associated virus (AAV) characterisation using cryo-electron microscopy. The event is hosted by DDW and supported by Thermo Fisher Scientific. In… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#News

#AAV #Cryo-EM #cryo-microscopy #Drug discovery #Gene therapy

Quantitative analysis of full and empty particles in adeno-associated virus vectors for gene therapy

In this event, Professor Susumu Uchiyama, Department of Biotechnology, Graduate School of Engineering, Osaka University, presents his work around adeno-associated virus (AAV) characterisation using cryo-electron microscopy. In recent years, AAV vectors have been launched and are considered one of the main platforms for gene therapy, with more than 250 clinical… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#Webinars

#AAV #Clinical trial #Duchenne muscular dystrophy #Gene therapy #REGENXBIO

Positive Phase I/II trial data for Duchenne gene therapy

New data has revealed a robust microdystrophin expression from a pivotal dose of gene therapy RGX-202 for Duchenne muscular dystrophy (Duchenne). RGX-202 is an investigational one-time AAV therapeutic designed to deliver a novel microdystrophin gene that includes key regions of the naturally occurring dystrophin gene. Read More

#News

Drug discovery innovation
#AAV #Cell and gene therapy #Drug development #Drug discovery #Gene therapy #Genetics / genomics #Immunology / Virology & Vaccines #Interview #Life sciences #Market reporting #Precision medicine #RNA #RNA sequencing #Scandinavia #Sweden #Transcriptomics

Podcast: Innovation drivers and opportunities for drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovation drivers and opportunities for drug discovery”, which covers three articles written Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Optimising AAV capsid purification through improved analytics How… Read More

#News

Human adenovirus
#AAV #Cell and gene therapy #Cell and Gene Therapy Catapult #Collaboration #Gene delivery

Cross-industry consortium to improve AAV formulation

The Cell and Gene Therapy Catapult (CGT Catapult) has established a cross-industry consortium to improve the understanding and process optimisation of adeno-associated virus (AAV) formulation. AAV-based gene therapies are being developed to treat a broad range of inherited and chronic diseases and several of these therapies have already… Read More

#News

#AAV #Astrea Bioseparations #Cell and gene therapy #Exosomes #Molecular Biology

The democratisation of cell and gene therapy

Marc Hummersone, Senior Director of Research and Development (R&D) at Astrea Bioseparations, shares insight on the challenges and opportunities in cell and gene therapy (CGT) with DDW’s Megan Thomas. Lack of standardisation According to Hummersone, the major challenge in the CGT space is a lack of throughput that’s due to… Read More

#Exclusive Content #Opinion #Trends & Analysis

#AAV #Gene therapy #Genetics / genomics #Genome sequencing #Recombinant DNA #Webinar

How can long-read nanopore sequencing support gene therapy delivery?

Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden,… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#AAV #Gene therapy #Genetics / genomics #Genome sequencing #Recombinant DNA #Webinar

Uncovering packaging impurities with rAAV genome sequencing

Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden,… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Gene sequence
#AAV #Gene therapy #Genetics / genomics #Genome sequencing #Recombinant DNA

How rAAV genome sequencing uncovers transgene integrity

Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden,… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#AAV #Gene therapy #Genetics / genomics #Genome sequencing #Recombinant DNA

DDW event focusses on rAAVs and long-read nanopore sequencing

Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden,… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#AAV #Gene therapy #Genetics / genomics #Genome sequencing #Recombinant DNA

rAAV Genome sequencing uncovers transgene integrity and packaging impurities

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar highlights how long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs were evaluated — which is supporting internal research activities at AstraZeneca. You will hear how library preparation, assessed data quality,… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#Webinars